The selective utilization of IRAK kinases, which are thought to be recruited to MyD88 to form the 'Myddosome', has been shown to differ substantially in mouse and human cells. This finding has important implications for the development of therapeutics for inflammatory and autoimmune disorders associated with Toll-like receptors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sun, J. et al. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Sci. Signal. 9, ra3 (2016).
Ferrao, R., Li, J., Bergamin, E. & Wu, H. Structural insights into the assembly of large oligomeric signalosomes in the Toll-like receptor-interleukin-1 receptor superfamily. Sci. Signal. 5, re3 (2012).
Lin, S. C., Lo, Y. C. & Wu, H. Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling. Nature 465, 885–890 (2010).
Burns, K. et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197, 263–268 (2003).
Medvedev, A. E. et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521–531 (2003).
Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076–2079 (2003).
Currie, A. J. et al. Primary immunodeficiency to pneumococcal infection due to a defect in Toll-like receptor signaling. J. Pediatr. 144, 512–518 (2004).
Medvedev, A. E. et al. Cutting edge: expression of IL-1 receptor-associated kinase-4 (IRAK-4) proteins with mutations identified in a patient with recurrent bacterial infections alters normal IRAK-4 interaction with components of the IL-1 receptor complex. J. Immunol. 174, 6587–6591 (2005).
Flannery, S. & Bowie, A. G. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem. Pharmacol. 80, 1981–1991 (2010).
Bahia, M. S., Kaur, M., Silakari, P. & Silakari, O. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cell. Signal. 27, 1039–1055 (2015).
Acknowledgements
This work was carried out with support from NIH AI018797 to S.N.V. The authors also thank Dr Andrei Medvedev for his helpful suggestions during the writing of this commentary.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Perkins, D., Vogel, S. Species-specific TLR signalling — insight into human disease. Nat Rev Rheumatol 12, 198–200 (2016). https://doi.org/10.1038/nrrheum.2016.36
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.36
This article is cited by
-
Kinase inhibition in autoimmunity and inflammation
Nature Reviews Drug Discovery (2021)
-
Toll-like receptors: promising therapeutic targets for inflammatory diseases
Archives of Pharmacal Research (2016)
